It turns out that Martin Shkreli endowed an NYU professorship, the Martin Shkreli Professor of Pediatric Nephrology. Current holder is Howard Trachtman who, according to The Huffington Post, “previously served as a consultant at Retrophin, where Shkreli was CEO.” The article goes on to quote NYU spokesperson Lisa Greiner, “We reviewed potential conflicts of interests at each step in the process, and there was no conflict when the gift was accepted. Should a review of the gift become necessary as the situation evolves, we will do so at that time.”
Another article, this one in the New York Daily News, describes Shkreli:
Shkreli, 32, emerged as the pharma world’s biggest villain this year when his company, Turing Pharmaceuticals, bought the lifesaving AIDS drug Daraprim and immediately shot up the price from $13.50 to $750 a pill.
Industry insiders accused him of targeting little-known drugs and then spiking the prices.
Another one of his companies, KaloBios, fired him as CEO just a month after he took over. The company stopped trading stocks after his arrest, and announced Wednesday it will soon be removed from NASDAQ. Its interim CEO and outside accounting firm have resigned.
I promised no comment, but I can’t resist asking: Just how important is money to the modern university?